{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:15:41Z","timestamp":1783134941602,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Tianjin Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["24JCYBJC00520"],"award-info":[{"award-number":["24JCYBJC00520"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270861"],"award-info":[{"award-number":["32270861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403171"],"award-info":[{"award-number":["82403171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118982","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:32:39Z","timestamp":1779305559000},"page":"118982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeted degradation of SETDB1 by an Aptamer-CRBNL PROTAC as a novel therapeutic strategy for breast cancer"],"prefix":"10.1016","volume":"315","author":[{"given":"Shuyu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingge","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-3781","authenticated-orcid":false,"given":"Chenghao","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118982_bib1","doi-asserted-by":"crossref","first-page":"108371","DOI":"10.1016\/j.pharmthera.2023.108371","article-title":"Novel strategies and promising opportunities for targeted protein degradation: an innovative therapeutic approach to overcome cancer resistance","volume":"244","author":"Zhu","year":"2023","journal-title":"Pharmacol Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118982_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118982_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.ejmech.2026.118982_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116166","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","volume":"267","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118982_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC technology: from drug development to probe technology for target deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118982_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118982_bib7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/2159-8290.CD-NB2020-054","article-title":"Proof-of-Concept with PROTACs in prostate cancer","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118982_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Martin-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118982_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118982_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118982_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116096","article-title":"Progress in the controllability technology of PROTAC","volume":"265","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118982_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.sbi.2016.01.009","article-title":"Embracing proteins: structural themes in aptamer-protein complexes","volume":"36","author":"Gelinas","year":"2016","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118982_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/nar\/24.6.1029","article-title":"RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity","volume":"24","author":"Geiger","year":"1996","journal-title":"Nucleic Acids Res."},{"issue":"32","key":"10.1016\/j.ejmech.2026.118982_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1502159112","article-title":"The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118982_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtn.2022.09.008","article-title":"Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118982_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1191","article-title":"Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC","volume":"13","author":"Kong","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118982_bib17","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.scib.2024.05.017","article-title":"An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer","volume":"69","author":"Kong","year":"2024","journal-title":"Sci. Bull."},{"issue":"26","key":"10.1016\/j.ejmech.2026.118982_bib18","article-title":"Antitumor effect of Anti-c-Myc aptamer-based PROTAC for degradation of the c-Myc protein","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.118982_bib19","article-title":"Dual aptamers-based SETDB1 PROTACs as effective anti-tumor strategies for breast cancer","author":"Guo","year":"2026","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118982_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/0008-5472.CAN-20-2906","article-title":"Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential","volume":"81","author":"Strepkos","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118982_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103982","article-title":"SETDB1, an H3K9-specific methyltransferase: an attractive epigenetic target to combat cancer","volume":"29","author":"Prashanth","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118982_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40659-018-0189-0","article-title":"Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation","volume":"51","author":"Wu","year":"2018","journal-title":"Biol. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118982_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5483\/BMBRep.2019.52.2.235","article-title":"SETDB1 regulates SMAD7 expression for breast cancer metastasis","volume":"52","author":"Ryu","year":"2019","journal-title":"BMB Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118982_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2020.04.047","article-title":"SETDB1 inhibits p53-Mediated apoptosis and is required for formation of pancreatic ductal adenocarcinomas in mice","volume":"159","author":"Ogawa","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118982_bib25","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1002\/ijc.32432","article-title":"Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target","volume":"145","author":"Orouji","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118982_bib26","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/JTO.0000000000000685","article-title":"Clinicopathological and survival analysis of Japanese patients with resected non-small-cell lung cancer harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA gene amplification","volume":"10","author":"Inoue","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.118982_bib27","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1038\/ncomms9651","article-title":"Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53","volume":"6","author":"Fei","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118982_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.13619","article-title":"SETDB1: a perspective into immune cell function and cancer immunotherapy","volume":"169","author":"Johnson","year":"2023","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118982_bib29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-22-0784","article-title":"The crossroads of cancer epigenetics and immune checkpoint therapy","volume":"29","author":"Micevic","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7866","key":"10.1016\/j.ejmech.2026.118982_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"Griffin","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118982_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2561-6","article-title":"SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression","volume":"11","author":"Cao","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118982_bib32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.15252\/embr.201744250","article-title":"Smad3-mediated recruitment of the methyltransferase SETDB1\/ESET controls expression and epithelial-mesenchymal transition","volume":"19","author":"Du","year":"2018","journal-title":"EMBO Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118982_bib33","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-20-2906","article-title":"Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential","volume":"81","author":"Strepkos","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118982_bib34","article-title":"High SET domain bifurcated 1 (SETDB1) expression predicts poor prognosis in breast carcinoma","volume":"26","author":"Zhou","year":"2020","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118982_bib35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/s41467-025-57005-3","article-title":"Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells","volume":"16","author":"Uguen","year":"2025","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118982_bib36","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1002\/anie.202017200","article-title":"Structure-guided discovery of a potent and selective cell-active inhibitor of SETDB1 tudor domain","volume":"60","author":"Guo","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118982_bib37","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1021\/acschembio.3c00280","article-title":"SETDB1 triple tudor domain ligand, (R,R)-59, promotes methylation of Akt1 in cells","volume":"18","author":"Uguen","year":"2023","journal-title":"ACS Chem. Biol."},{"issue":"8082","key":"10.1016\/j.ejmech.2026.118982_bib38","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","article-title":"NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity","volume":"645","author":"Heide","year":"2025","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ejmech.2026.118982_bib39","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res."},{"issue":"717","key":"10.1016\/j.ejmech.2026.118982_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add2712","article-title":"Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118982_bib41","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118982_bib42","doi-asserted-by":"crossref","unstructured":"J. M. Tsai, R. P. Nowak, B. L. Ebert, E. S. Fischer. Targeted protein degradation: from mechanisms to clinic. Nat. Rev. Mol. Cell Biol., 25 (9), 2024, 740.","DOI":"10.1038\/s41580-024-00729-9"},{"issue":"Sup4","key":"10.1016\/j.ejmech.2026.118982_bib43","doi-asserted-by":"crossref","first-page":"103240","DOI":"10.1016\/j.esmoop.2024.103240","article-title":"218P vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (Palbo) in ER+\/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase Ib cohort results","volume":"9","author":"Hamilton","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2026.118982_bib44","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"1","author":"Griffin","year":"2021","journal-title":"Nature"},{"issue":"7882","key":"10.1016\/j.ejmech.2026.118982_bib45","first-page":"682","article-title":"KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements","volume":"598","author":"Zhang","year":"2021"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118982_bib46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1021\/acs.jmedchem.2c01557","article-title":"Inducible degradation of oncogenic nucleolin using an aptamer-based PROTAC","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118982_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11427-020-1765-6","article-title":"Redox-dependent regulation of end-binding protein 1 activity by glutathionylation","volume":"64","author":"Chen","year":"2021","journal-title":"Sci. China Life Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118982_bib48","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/ajco.13550","article-title":"Enkurin domain containing 1 (ENKD1) regulates the proliferation, migration and invasion of non-small cell lung cancer cells","volume":"18","author":"Song","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:19:23Z","timestamp":1783131563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S0223523426004277"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118982","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted degradation of SETDB1 by an Aptamer-CRBNL PROTAC as a novel therapeutic strategy for breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118982"}}